Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 18214995)

1.

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer.

Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X.

Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169.

PMID:
18214995
2.

Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.

Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, Wang XW.

Gastroenterology. 2012 Apr;142(4):957-966.e12. doi: 10.1053/j.gastro.2011.12.039. Epub 2011 Dec 24.

3.

Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.

Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, Calvisi DF, Chen X.

J Hepatol. 2012 Sep;57(3):577-83. doi: 10.1016/j.jhep.2012.04.026. Epub 2012 May 19.

4.

Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.

Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X, Calvisi DF.

Hepatology. 2010 Aug;52(2):506-17. doi: 10.1002/hep.23681.

5.

Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.

Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR.

Cancer Res. 2006 Feb 15;66(4):2048-58.

6.

Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer.

Fan B, Dachrut S, Coral H, Yuen ST, Chu KM, Law S, Zhang L, Ji J, Leung SY, Chen X.

PLoS One. 2012;7(4):e29824. doi: 10.1371/journal.pone.0029824. Epub 2012 Apr 23.

7.

Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.

Patil MA, Gütgemann I, Zhang J, Ho C, Cheung ST, Ginzinger D, Li R, Dykema KJ, So S, Fan ST, Kakar S, Furge KA, Büttner R, Chen X.

Carcinogenesis. 2005 Dec;26(12):2050-7. Epub 2005 Jul 6.

8.

Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W.

Mol Cancer Res. 2007 May;5(5):509-20.

9.

Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.

Zhang J, Lan SJ, Liu QR, Liu JM, Chen XQ.

Mol Pharmacol. 2013 May;83(5):1109-19. doi: 10.1124/mol.112.083634. Epub 2013 Mar 11.

11.
12.

Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice.

Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Domany E, Galun E, Goldenberg D.

Mol Cancer Res. 2007 Nov;5(11):1159-70.

13.

Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells.

Walsh AM, Lazzara MJ.

J Cell Sci. 2013 Oct 1;126(Pt 19):4339-48. doi: 10.1242/jcs.123208. Epub 2013 Jul 18.

14.

Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma.

Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, Fu L, Zhang N, Tong AH, Qin YR, Tsao SW, Chan KW, Lok S, Guan XY.

Gastroenterology. 2012 Sep;143(3):675-86.e1-12. doi: 10.1053/j.gastro.2012.06.007. Epub 2012 Jun 13.

PMID:
22705009
15.

Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells.

Wei W, Chua MS, Grepper S, So SK.

Mol Cancer. 2009 Sep 24;8:76. doi: 10.1186/1476-4598-8-76.

16.

Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer.

Chan DW, Chan CY, Yam JW, Ching YP, Ng IO.

Gastroenterology. 2006 Oct;131(4):1218-27. Epub 2006 Jul 24.

PMID:
17030191
17.

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W.

Hepatology. 2015 Jan;61(1):214-26. doi: 10.1002/hep.27402. Epub 2014 Nov 25.

PMID:
25163657
18.

Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.

Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B.

Gastroenterology. 2012 Sep;143(3):811-20.e1-15. doi: 10.1053/j.gastro.2012.05.033. Epub 2012 May 26.

PMID:
22641068
19.

Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.

Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.

Cancer Res. 2011 Apr 1;71(7):2718-27. doi: 10.1158/0008-5472.CAN-10-2705. Epub 2011 Feb 15.

20.

The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer.

Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, Putti TC, Guy GR.

Cancer Res. 2004 Sep 1;64(17):6127-36.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk